Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims align with the label’s boxed warning (opioids) and general benzodiazepine risks (sedation/respiratory depression; abuse/misuse/addiction; dependence/withdrawal; tapering). However, many COPD-/sleep-/oxygen-related and specific severity/conditional-risk statements are not supported by the provided label excerpts, and one claim about “risk from benzodiazepines may be higher during sleep” is not directly supported in the supplied label text.
Category Scores
Accurate Statements
Concomitant use of Ativan (lorazepam) with opioids may result in profound sedation, respiratory depression, coma, and death.
Supported by label Boxed Warning/Warnings (concomitant benzodiazepines + opioids) and Drug Interactions.
Concomitant use with opioids increases the risk of respiratory depression.
Supported by label Drug Interactions and Warnings (increased risk of respiratory depression with opioids).
Benzodiazepines (including Ativan) can cause sedation.
Supported by label Adverse Reactions (sedation is most frequent adverse reaction).
Benzodiazepines/Ativan can cause respiratory depression and may worsen obstructive lung disease/sleep apnea.
Supported by label Adverse Reactions listing respiratory depression/apnea/worsening of sleep apnea and worsening obstructive pulmonary disease.
Benzodiabenzepines/Ativan have risks of abuse, misuse, and addiction, which can lead to overdose or death.
Supported by label Warnings (Abuse, Misuse, and Addiction).
Continued use may lead to physical dependence; abrupt discontinuation or rapid reduction may precipitate life-threatening withdrawal reactions (e.g., seizures).
Supported by label Warnings (Dependence and Withdrawal Reactions) and Dosage/Administration (gradual taper).
Use a gradual taper to discontinue or reduce Ativan to reduce risk of withdrawal.
Supported by label Dosage and Administration.
Unsupported Statements
Benzodiazepines can depress breathing.
The label excerpts support respiratory depression/apnea, but this specific phrasing is broader than the provided excerpts and is not explicitly stated as a standalone general statement.
The risk from benzodiazepines may be higher during sleep.
Not directly supported in the supplied label excerpts.
The risk from benzodiazepines may be higher if there are other risk factors for low oxygen or respiratory depression.
Not directly supported as a general statement in the supplied label excerpts.
Clinicians often try to avoid or limit benzodiazepines in COPD unless the benefit clearly outweighs the risk.
The supplied excerpts list benzodiazepine risks of worsening obstructive pulmonary disease, but do not support this specific COPD management/clinical-practice framing.
Ativan can slow breathing.
The label excerpts support respiratory depression/apnea, but this specific phrasing is not explicitly stated.
Ativan can reduce the body’s drive to breathe.
Not directly supported by the supplied label excerpts.
Increased sedation from Ativan can affect airway protection during sleep.
Not directly supported by the supplied label excerpts.
Ativan can raise the risk of low oxygen levels.
Not directly stated in the supplied excerpts.
The risk of low oxygen levels from Ativan is higher when COPD is severe.
Not supported in the supplied label excerpts (severity-specific low-oxygen risk not provided).
Examples of other sedating medicines include sleep medications, some antihistamines, and muscle relaxants.
The label excerpt mentions other CNS depressants (and alcohol/barbiturates/narcotic analgesics) but does not provide these specific examples in the supplied text.
Combining Ativan with opioids or other sedatives is a common trigger for dangerous breathing suppression.
Label supports risk with concomitant opioids/CNS depressants, but the “common trigger” framing is not supported by the supplied excerpts.
In COPD, advanced disease increases the risk of benzodiazepine-related breathing suppression with Ativan.
Not directly supported by the supplied excerpts.
Sleep-related breathing problems (including sleep apnea) increase the risk of benzodiazepine-related breathing suppression with Ativan.
The label excerpt supports worsening of sleep apnea, but does not explicitly state an increased risk of “breathing suppression” or condition-specific risk escalation.
A history of low oxygen increases the risk of benzodiazepine-related breathing suppression with Ativan.
Not supported in the supplied excerpts.
Frequent exacerbations increase the risk of benzodiazepine-related breathing suppression with Ativan.
Not supported in the supplied excerpts.
Using the lowest effective dose for the shortest possible time is a key precaution with Ativan in COPD.
Lowest effective dose/minimum duration guidance is supported for concomitant opioid prescribing, but the statement is specifically framed for COPD and is not supported in the supplied excerpts.
Avoiding dose escalations without medical guidance is a key precaution with Ativan in COPD.
Not directly supported by the supplied excerpts.
Not taking Ativan with alcohol is a key precaution.
The label excerpt supports increased CNS-depressant effects with alcohol (as a CNS depressant), but the phrasing “Not taking… is a key precaution” is not explicitly stated as such in the supplied excerpts.
Avoiding other sedating drugs unless the prescriber explicitly approves is a key precaution.
Label excerpt supports avoiding/minimizing concomitant CNS depressants, but does not include the “explicitly approves” wording in the supplied excerpts.
Emergency help should be sought if there are signs of excessive sedation or breathing problems after taking Ativan. Signs include very slow or difficult breathing, unresponsiveness or inability to stay awake, bluish lips or fingers, and severe confusion.
The label excerpts provided do not include this specific emergency-action instruction or the specific sign list.
Contradictions
Important Omissions
Ativan indicated use is for anxiety disorders/short-term relief of anxiety (with reassessment for usefulness), which is not addressed by the AI response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While major label-backed warnings about opioid coadministration and sedation/respiratory depression are present, several COPD/sleep/low-oxygen severity and emergency-sign statements are not supported by the supplied label text and may lead to overconfident or misdirected risk communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Many statements are COPD- and sleep-conditional risk claims (including low-oxygen and emergency action/sign lists) that are not supported by the provided label excerpts, despite some correct general warnings.
Suggested Improvement
Limit claims to the supplied label excerpts: (1) opioid coadministration boxed warning/interaction mitigation language; (2) abuse/misuse/addiction; (3) dependence/withdrawal and gradual taper; (4) label-supported adverse reactions (sedation; respiratory depression/apnea; worsening sleep apnea/obstructive pulmonary disease). Remove or rephrase unsupported COPD severity, low-oxygen risk, and the detailed emergency sign list unless present in the label text.